Nightingale Health Plc’s (“Nightingale Health”) Board of Directors has resolved to launch a stock option program for the company’s newest management team member Janna Ranta in accordance with the established practice for stock option rights in the management team.

The right to subscribe for shares is earned solely based on an increase in Nightingale Health’s market capitalization.

The purpose of Nightingale Health’s stock option programs is to bind the option holders to the company’s economic growth and the development of its market capitalization, as well as create a long-term relationship between the company and its option holders that benefits the company economically and operationally. The decision to launch the new stock option program was made based on the authorization granted by the Extraordinary General Meeting held on 18 February 2021.

Each option right entitles the option holder to subscribe for one Series B share. The subscription price of each share is EUR 2.50 per share. The total number of stock option rights that can be issued under the new stock option programs is 339,800, entitling the holder to subscribe for a maximum of 339,800 Series B shares. 

The right to subscribe for shares is earned upon reaching the following market capitalization steps, calculated with the volume weighted average price: 1,000 million, 1,250 million and 1,500 million euros. The share subscription period for the stock option program ends on 31 May 2035.